In conclusion, we have shown that a histochemical evaluation of survivin expression in pretreatment biopsies of patients with anal carcinoma provides an easy accessible molecular indicator to identify patients at risk of distant metastatic disease. Here, BIRC5 is linked to anal carcinoma.